logo

SKYE

Skye Bioscience·NASDAQ
--
--(--)
--
--(--)

SKYE fundamentals

Skye Bioscience (SKYE) released its earnings on Mar 10, 2026: revenue was 0 (YoY --), met estimates; EPS was -0.36 (YoY -50.00%), missed estimates.
Revenue / YoY
0
--
EPS / YoY
-0.36
-50.00%
Report date
Mar 10, 2026
SKYE Earnings Call Summary for Q4,2025
  • CBeyond Expansion Launched: Higher doses (400-600 mg IV) to confirm efficacy and safety, targeting 16-week data in Q4 2026.
  • APC Program Breakthrough: Unimolecular construct achieves 14% weight loss, with potential for 3-day dosing.
  • GLP-1 Add-On Focus: Phase IIb designed for second-line patients, leveraging nimacimab's orthogonal mechanism.
  • Financial Stability: $25.7M cash runway through Q4 2026, supporting clinical milestones.
EPS
Revenue

Revenue & Expenses

Key Indicators

Skye Bioscience (SKYE) key financial stats and ratios, covering profitability, financial health, and leverage.
Skye Bioscience (SKYE)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Skye Bioscience (SKYE)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Skye Bioscience (SKYE)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Skye Bioscience (SKYE) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Skye Bioscience (SKYE) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield